Navigation Links
Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share
Date:2/4/2009

SEATTLE, Feb. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today that it has issued 6,634 shares of Series F Preferred Stock in exchange for 6,634 shares of CTI's Series A, B and C Convertible Preferred Stock. The exchange constitutes 83% in interest of all series of CTI's Convertible Preferred Stock. Each share of the new Preferred Stock will become convertible into 7,143 shares of CTI's common stock, at a conversion price of $0.14 per common share representing a significant premium to the current market price.

The Series F Preferred Stock cannot become convertible into common stock sooner than April 1, 2009. Additionally, the Company has the ability to redeem all, but not less than all, of the outstanding Series F Preferred Stock for cash when the Volume-Weighted Average Price (VWAP) has exceeded $0.28 for ten previous trading days. The Series F Preferred Stock does not provide a redemption right for the holders as did the Series A, B and C Convertible Preferred Stock, thereby eliminating the possibility that the Company could be required to make involuntary cash redemption payments of approximately $6.6 million on the preferred stock that was exchanged. The Series F Preferred Stock does not bear a fixed dividend rate.

"We are pleased that almost all of the remaining preferred shareholders were willing to trade in their securities and enable CTI to avoid their redemption rights and dividend payments, saving the company approximately $6.6 million over the next 6 months, for a meaningful equity position in the Company upon their conversion into common stock," noted James A. Bianco, M.D., CEO of CTI. "With the prospects for three drug approvals in 2009, we believe they chose to participate based on the price appreciation potential of CTI should we be successful with the approvals this year."

About Cell Therapeutics, Inc.

Headquartered i
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
2. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
3. Omnitura Therapeutics Announces Private Placement Financing
4. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
5. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
6. CV Therapeutics Statement on Unsolicited Proposal From Astellas
7. Cell Therapeutics Receives Additional NASDAQ Notification
8. Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes
9. Frost & Sullivan Recognizes ESBATechs Innovation in Developing Antibody Fragments for Biologic Therapeutics
10. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
11. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... November 27, 2014 Calcivis, ... management of tooth decay, today announces that it ... Calcivis® Caries Activity Imaging System. The ... medical device and consumable combination designed to transform ... decay). It involves a unique, proprietary bioluminescence approach ...
(Date:11/26/2014)... 2014 Deep Research Report on ... in-depth research report on the Ammonium Bifluoride market, ... classification, application, and industry chain structure as well ... market analysis, including China’s domestic market as well ... China, Japan etc. regions) industry analysis covering macroeconomic ...
(Date:11/26/2014)... and PHILADELPHIA , Nov. 26, 2014 ... and unforgiving environments. Human exploration of space requires astronauts ... ensure mission safety and success, and prevent potential errors ... mission success, little is known about how cognition is ... are primarily affected. Now, Penn Medicine researchers ...
(Date:11/26/2014)... 26, 2014 PMG Research, Inc. ... Research is a network of sites that provide clinical research ... 2 million patient lives through its partnerships with large physician ... 11 hub site locations in the Southeastern United States and ... of the board will be held by: Dr. ...
Breaking Biology Technology:Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 3Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3
... and Yale universities have successfully transplanted most of the "nose" ... fruit flies and are employing these surrogates to combat the ... million people. The research is described in two complimentary ... of the Proceedings of the National Academy of Sciences ...
... ... World Europe conference in Brussels addresses the 4 key pillars of ... of the algae value chain. Panel of industry experts will also ... pharmaceuticals, nutraceuticals, cosmetics, aquaculture feed, bioplastics, coatings, etc. The program includes ...
... Feb. 12 CoAxia™, Inc. of Maple Grove, ... SENTIS randomized, controlled, pivotal trial of NeuroFlo™ Perfusion Augmentation Therapy ... plans to complete data collection and analysis of results in ... the US FDA. , Ischemic stroke is one of the ...
Cached Biology Technology:Scientists transplant nose of mosquito, advance fight against malaria 2Scientists transplant nose of mosquito, advance fight against malaria 32nd Algae World Europe Tracks Algae Commercialization from Algae Production to High-value Products- Nutraceuticals, Aquaculture Feed, Cosmetics, Biofuels and More 22nd Algae World Europe Tracks Algae Commercialization from Algae Production to High-value Products- Nutraceuticals, Aquaculture Feed, Cosmetics, Biofuels and More 3CoAxia Announces Completion of Enrollment in Ischemic Stroke Trial 2CoAxia Announces Completion of Enrollment in Ischemic Stroke Trial 3
(Date:11/5/2014)... Brazil -Individuals show great diversity in their ability to ... females greatly differ in their perceptual evaluation of odors, ... tests. , Sex differences in olfactory detection ... may be connected to one,s perception of smell, which ... women,s olfactory superiority has been suggested to be cognitive ...
(Date:11/4/2014)... only marketing directed at children on the interior ... that the majority of black, middle-income and rural ... , Authored by Arizona State University researcher Punam ... first to examine the use of child-directed marketing ... restaurants and its relationship to demographics. It adds ...
(Date:11/3/2014)... Cancer Center study published in this month,s ... describes the activity of a recently discovered communication molecule ... It has been known to limit inflammation and the ... system: IL-37 inhibits the ability of the immune system ... mechanism that underlies IL-37,s effect on the immune system ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... King,s College London will today (Tuesday 6 December) announce ... (UKSCB) their first clinical grade human embryonic stem (hES) ... as ,xeno-free, stem cells. The cells, which have ... developing new stem cell-based therapies, will be the first ...
... Thanks to a new study of the retina, scientists ... how the nervous system becomes wired during early development. ... research at UCSB. The work is described in a recent ... research team examined the connectivity of nerve cells, called neurons, ...
... - Researchers have demonstrated a new imaging tool for ... the bloodstream, which could aid efforts to perfect their ... structures have potential applications in drug delivery to treat ... nanotubes are created in the manufacturing process, metallic and ...
Cached Biology News:Stem cell research in the UK reaches significant milestone 2Stem cell research in the UK reaches significant milestone 3Stem cell research in the UK reaches significant milestone 4UCSB scientists make advances in neuroscience and vision research 2UCSB scientists make advances in neuroscience and vision research 3'Label-free' imaging tool tracks nanotubes in cells, blood for biomedical research 2
... Kit, Protein, 1. Based on the ... the kit gives essentially colorless backgrounds ... Kit, Protein provides convenient, reproducible and ... gels in less than two hours.The ...
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
Natural Mouse Laminin is purified from the Engelbreth-Holm-Swarm (EHS) sarcoma and is provided in Tris-buffered saline....
... • Guinea Pig serum is collected from ... N-02: Citrate N-04: Heparin ... Potassium Oxalate N-10: EDTA (Na) ... N-07: CPD N-09: K3EDTA ...
Biology Products: